top of page
検索

Zealand Pharma initiates Phase II ZYNERGY trial combining petrelintide and enicepatide for obesity

執筆者の写真: nuaxia
nuaxia
2 日前
読了時間: 1分

Zealand Pharma has launched the Phase II ZYNERGY study to assess combined amylin and GLP-1/GIP receptor activity in obesity, advancing a potential multi-mechanism weight-management approach.


Zealand Pharma announced on 18 November 2026 that it had initiated the Phase II ZYNERGY dose-finding trial evaluating petrelintide, an amylin analogue, co-administered with enicepatide, a GLP-1/GIP receptor agonist, in people with obesity or overweight and at least one weight-related comorbidity.


The study will evaluate three combination dosing regimens over 40 weeks to investigate weight-loss potential, cardiometabolic outcomes and tolerability, representing an important clinical development milestone but not an announcement of positive efficacy results or regulatory approval.

Field

Content

Company

Zealand Pharma

Clinical Trial

ZYNERGY

Announcement Date

18 November 2026

Development Milestone

Phase II trial initiation

Clinical Development Phase

Phase II

Therapeutic Area

Obesity and metabolic disease

Investigational Combination

Petrelintide plus enicepatide

Medicine One

Petrelintide

Medicine One Mechanism

Amylin analogue

Medicine Two

Enicepatide

Medicine Two Mechanism

GLP-1/GIP receptor agonist

Eligible Population

People with obesity or overweight and at least one weight-related comorbidity

Study Design

Dose-finding study evaluating three combination dosing regimens

Treatment Duration

40 weeks

Key Study Objectives

Assess weight-loss potential cardiometabolic outcomes and tolerability

Regulatory Status

Investigational combination; trial initiation does not constitute efficacy confirmation or approval

Primary Source

https://rss.globenewswire.com/news-release/2026/11/18/3405372/0/en/zealand-pharma-announces-initiation-of-the-phase-2-zynergy-trial-of-petrelintide-co-administered-with-enicepatide-in-people-with-obesity-or-overweight.html


Discover how nuaxia can support your next medical education initiative:

 
 
 

コメント

5つ星のうち0と評価されています。
まだ評価がありません

評価を追加
bottom of page